CTMX Cytomx Therapeutics, Inc.

$2.19 -1.35%

Data as of Nov 3, 2026 close

Healthcare · Pharmaceutical Preparations

Cytomx Therapeutics, Inc. (CTMX) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $477 million. Shares last traded at $2.19, 73.3% below their 52-week high. Over the past year the stock is down 38.8%. Net profit margin is -104.5%, below the peer median of -7.4%. Revenue declined 44.8% year over year.

Market Cap

$477M

Shares Out

217.9M

EPS (TTM)

—

P/E (TTM)*

—

P/S Ratio

6.26

P/B Ratio

1.58

Dividend / Share

—

Dividend Yield

—

52-Week High

$8.20

52-Week Low

$2.14

Volume (venue)

336,516

Avg Vol (3m, venue)

306,836.762

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

-5.60%

-15.61%

-34.43%

-46.45%

YTD

-48.77%

-38.83%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

38.38

SMA (50)

$2.78

SMA (200)

$3.85

Price vs SMA50

-21.30%

Price vs SMA200

-43.06%

ATR (14)

$0.16

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$76M

Net Income

-$80M

Gross Margin

—

Operating Margin

-114.4%

Net Margin

-104.5%

Return on Equity

-26.4%

Return on Assets

-20.9%

Current Ratio

9.36

Debt / Equity

0.01

Revenue Growth (YoY)

-44.8%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Pharmaceutical Preparations peers

CTMX vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of Nov 3, 2026 close

P/S vs peers

6.26 / 7.65 med

-18% discount

Net margin vs peers

-104.5% / -7.4% med

below median

1–14 of 14


LLY	Lilly (Eli)	$1.33T	48.07	15.33	31.9%	-0.12%
JNJ	Johnson & Johnson	$640.8B	39.81	6.45	16.2%	-1.76%
ONC	Beone Medicines Ltd.	$524.6B	800.05	85.59	10.7%	-1.72%
ABBV	AbbVie	$503.8B	48.71	7.63	15.7%	-1.30%
MRK	Merck	$356.9B	112.49	5.36	4.8%	-2.57%
ABT	Abbott Laboratories	$190.6B	30.37	4.22	13.9%	-0.78%
PFE	Pfizer	$171.2B	42.46	2.69	6.3%	-2.18%
VRTX	Vertex Pharmaceuticals	$134.7B	33.87	10.40	30.7%	-6.81%
BMY	Bristol Myers Squibb	$126.1B	13.65	2.52	18.5%	-2.09%
REGN	Regeneron Pharmaceuticals	$100.7B	20.91	5.96	28.5%	+1.30%
TEVA	Teva Pharmaceutical Industries Ltd	$48.9B	96.62	2.84	2.9%	+3.00%
ZTS	Zoetis	$34.3B	13.11	3.60	27.5%	-0.18%
RPRX	Royalty Pharma Plc	$29.5B	36.25	11.65	32.1%	-0.26%
ROIV	Roivant Sciences Ltd.	$26.0B	—	3458.17	—	+0.47%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.